ArticleJournal of virology2010
Recovery of replication-competent residual HIV-1 from plasma of a patient receiving prolonged, suppressive highly active antiretroviral therapy.
Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Neurosymptomatic HIV-1 CSF escape is associated with replication in CNS T cells and inflammation.The Journal of clinical investigation · 2024Article
- Sequence Analysis of Inducible, Replication-Competent Virus Reveals No Evidence of HIV-1 Evolution During Suppressive Antiviral Therapy, Indicating a Lack of Ongoing Viral Replication.Open forum infectious diseases · 2024Article
- Nonsuppressible viremia during HIV-1 therapy meets molecular virology.The Journal of clinical investigation · 2023Article
- Plasma-Derived HIV-1 Virions Contain Considerable Levels of Defective Genomes.Journal of virology · 2022Article
- Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.PLoS pathogens · 2020Observational
- Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites.Journal of virology · 2020Article
- Prolonged persistence of a novel replication-defective HIV-1 variant in plasma of a patient on suppressive therapy.Virology journal · 2016Article
- Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.Retrovirology · 2016Article
- Persistent HIV-1 replication during antiretroviral therapy.Current opinion in HIV and AIDS · 2016Review
- Measuring the latent reservoir in vivo.The Journal of clinical investigation · 2016Review
- Towards an HIV-1 cure: measuring the latent reservoir.Trends in microbiology · 2015Review
- Potential implication of residual viremia in patients on effective antiretroviral therapy.AIDS research and human retroviruses · 2015Review
- The use of Nanotrap particles technology in capturing HIV-1 virions and viral proteins from infected cells.PloS one · 2014Article
- Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.Journal of virology · 2013Article
- Dissecting the dynamics of HIV-1 protein sequence diversity.PloS one · 2013Article
- Review
- Deep molecular characterization of HIV-1 dynamics under suppressive HAART.PLoS pathogens · 2011Article
- Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure.PLoS pathogens · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The clinical significance of persistent residual viremia in patients on prolonged highly active antiretroviral therapy (HAART) is not clear. Moreover, it remains to be demonstrated whether residual viremia consists of viruses capable of spreading infection in vivo upon termination of therapy. Using residual viral RNAs (vRNAs) isolated from a HAART-treated patient's plasma, we cloned full-length viral genomes and found that most of them could produce infectious, replication-competent HIVs when transfected into TZM-bl cells, suggesting that residual viruses produced in the absence of therapy can initiate fresh cycles of infection and spread in host cells. The data further indicate that residual viremia may pose a major concern with regard to the emergence of drug-resistant HIVs during periods of low adherence to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.